Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

    Cancer Categories
    • Breast
    Karmanos Trial ID
    • 2023-031
    NCT ID
    • NCT05774951
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator

    Objective:

    Primary Efficacy Objectives:

    • To demonstrate superiority of extended therapy
      with camizestrant as compared to standard ET
      by assessment of invasive breast cancer-free
      survival (IBCFS).

    Key Secondary Efficacy Objectives:

    • To demonstrate superiority of extended therapy
      with camizestrant as compared to standard ET
      by assessment of invasive disease-free survival
      (IDFS).
    • To demonstrate superiority of extended therapy
      with camizestrant as compared to standard ET by 
      assessment of distant relapse-free survival
      (DRFS).
    • To demonstrate superiority of extended therapy
      with camizestrant as compared to standard ET
      by assessment of overall survival (OS).

    Safety Objectives:

    • To assess the safety of extended therapy with
      camizestrant as compared to standard ET.

    Clinical Outcome Assessments (COAs) Objectives:

    • To assess patient-reported treatment-associated
      symptoms of arthralgia, hot flush, and vaginal
      dryness of camizestrant as compared to
      standard ET.
    • To assess patient-reported health-related QoL in
      patients treated with extended therapy with
      camizestrant relative to standard ET.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at McLaren Greater Lansing - Medical Oncology and Hematology

    3520 Forest Rd.
    Lansing, MI 48910
    Get Directions
    Phone: 517-975-9500

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266